Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.

Cleary JM, McRee AJ, Shapiro GI, Tolaney SM, O'Neil BH, Kearns JD, Mathews S, Nering R, MacBeath G, Czibere A, Sharma S, Korn WM.

Invest New Drugs. 2017 Feb;35(1):68-78. doi: 10.1007/s10637-016-0399-7. Epub 2016 Nov 16.

PMID:
27853996
2.

Note: A portable laser induced breakdown spectroscopy instrument for rapid sampling and analysis of silicon-containing aerosols.

McLaughlin RP, Mason GS, Miller AL, Stipe CB, Kearns JD, Prier MW, Rarick JD.

Rev Sci Instrum. 2016 May;87(5):056103. doi: 10.1063/1.4949506.

3.

Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease.

Corti D, Kearns JD.

Curr Opin Immunol. 2016 Jun;40:51-61. doi: 10.1016/j.coi.2016.03.001. Epub 2016 Mar 23. Review.

PMID:
26995095
4.

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di Nicolantonio F, Nering R, Bardelli A.

Sci Transl Med. 2016 Feb 3;8(324):324ra14. doi: 10.1126/scitranslmed.aad5640.

5.

IκBβ enhances the generation of the low-affinity NFκB/RelA homodimer.

Tsui R, Kearns JD, Lynch C, Vu D, Ngo KA, Basak S, Ghosh G, Hoffmann A.

Nat Commun. 2015 May 7;6:7068. doi: 10.1038/ncomms8068.

6.

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.

Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM, Fitzgerald JB, Nielsen UB, Wolf BB.

Mol Cancer Ther. 2015 Jul;14(7):1625-36. doi: 10.1158/1535-7163.MCT-14-0772. Epub 2015 Apr 24.

7.

Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.

Harms BD, Kearns JD, Iadevaia S, Lugovskoy AA.

Methods. 2014 Jan 1;65(1):95-104. doi: 10.1016/j.ymeth.2013.07.017. Epub 2013 Jul 18.

PMID:
23872324
8.

Dual delayed feedback provides sensitivity and robustness to the NF-κB signaling module.

Longo DM, Selimkhanov J, Kearns JD, Hasty J, Hoffmann A, Tsimring LS.

PLoS Comput Biol. 2013;9(6):e1003112. doi: 10.1371/journal.pcbi.1003112. Epub 2013 Jun 27.

9.

Control of RelB during dendritic cell activation integrates canonical and noncanonical NF-κB pathways.

Shih VF, Davis-Turak J, Macal M, Huang JQ, Ponomarenko J, Kearns JD, Yu T, Fagerlund R, Asagiri M, Zuniga EI, Hoffmann A.

Nat Immunol. 2012 Dec;13(12):1162-70. doi: 10.1038/ni.2446. Epub 2012 Oct 21.

10.

Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.

Harms BD, Kearns JD, Su SV, Kohli N, Nielsen UB, Schoeberl B.

Methods Enzymol. 2012;502:67-87. doi: 10.1016/B978-0-12-416039-2.00004-5.

PMID:
22208982
11.

Nuclear export of the NF-κB inhibitor IκBα is required for proper B cell and secondary lymphoid tissue formation.

Wuerzberger-Davis SM, Chen Y, Yang DT, Kearns JD, Bates PW, Lynch C, Ladell NC, Yu M, Podd A, Zeng H, Huang TT, Wen R, Hoffmann A, Wang D, Miyamoto S.

Immunity. 2011 Feb 25;34(2):188-200. doi: 10.1016/j.immuni.2011.01.014. Epub 2011 Feb 17. Erratum in: Immunity. 2011 Mar 25;34(3):449.

12.

Kinetic control of negative feedback regulators of NF-kappaB/RelA determines their pathogen- and cytokine-receptor signaling specificity.

Shih VF, Kearns JD, Basak S, Savinova OV, Ghosh G, Hoffmann A.

Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9619-24. doi: 10.1073/pnas.0812367106. Epub 2009 Jun 1.

13.

HLA-A amino acid polymorphism and delayed kidney allograft function.

Kamoun M, Holmes JH, Israni AK, Kearns JD, Teal V, Yang WP, Rosas SE, Joffe MM, Li H, Feldman HI.

Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18883-8. doi: 10.1073/pnas.0810308105. Epub 2008 Nov 24.

14.

Integrating computational and biochemical studies to explore mechanisms in NF-{kappa}B signaling.

Kearns JD, Hoffmann A.

J Biol Chem. 2009 Feb 27;284(9):5439-43. doi: 10.1074/jbc.R800008200. Epub 2008 Oct 20. Review. No abstract available.

15.

Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20.

Werner SL, Kearns JD, Zadorozhnaya V, Lynch C, O'Dea E, Boldin MP, Ma A, Baltimore D, Hoffmann A.

Genes Dev. 2008 Aug 1;22(15):2093-101. doi: 10.1101/gad.1680708.

16.

UV as an amplifier rather than inducer of NF-kappaB activity.

O'Dea EL, Kearns JD, Hoffmann A.

Mol Cell. 2008 Jun 6;30(5):632-41. doi: 10.1016/j.molcel.2008.03.017.

17.

Stabilization of RelB requires multidomain interactions with p100/p52.

Fusco AJ, Savinova OV, Talwar R, Kearns JD, Hoffmann A, Ghosh G.

J Biol Chem. 2008 May 2;283(18):12324-32. doi: 10.1074/jbc.M707898200. Epub 2008 Mar 4.

18.

A homeostatic model of IkappaB metabolism to control constitutive NF-kappaB activity.

O'Dea EL, Barken D, Peralta RQ, Tran KT, Werner SL, Kearns JD, Levchenko A, Hoffmann A.

Mol Syst Biol. 2007;3:111. Epub 2007 May 8.

19.

A fourth IkappaB protein within the NF-kappaB signaling module.

Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM, Hoffmann A.

Cell. 2007 Jan 26;128(2):369-81.

20.

IkappaBepsilon provides negative feedback to control NF-kappaB oscillations, signaling dynamics, and inflammatory gene expression.

Kearns JD, Basak S, Werner SL, Huang CS, Hoffmann A.

J Cell Biol. 2006 Jun 5;173(5):659-64. Epub 2006 May 30.

Supplemental Content

Loading ...
Support Center